Study wrapper · #970
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.
Son JW, le Roux CW, Blüher M, et al. Endocrine reviews. 2026.
DOI: 10.1210/endrev/bnaf036PubMed: 41054801
SupportedReviewMentions: RetatrutideMentions: CagrilintideMentions: SemaglutideMentions: Tirzepatide
Editor's note
A broad review of emerging GLP-1-based and multireceptor agents for obesity and diabetes. Several tracked peptides appear, including retatrutide, CagriSema (cagrilintide plus semaglutide), and tirzepatide as an established benchmark. Useful landscape context rather than primary data.
Plain-language abstract
This review surveys next-generation GLP-1-based therapies for type 2 diabetes and obesity, including retatrutide, cagrilintide, semaglutide, and tirzepatide.
Related coverage
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026
Supported
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
iSciencen=——2026
Supported
CARDIOVASCULAR EFFECTS OF INCRETIN RECEPTOR AGONISTS: BEYOND GLYCEMIC CONTROL.
Canadian journal of physiology and pharmacologyn=——2026